Serum Institute Vaccines Profile
Key Indicators
- Authorised Capital ₹ 1,200.00 Cr
as on 14-12-2024
- Paid Up Capital ₹ 113.26 Cr
as on 14-12-2024
- Company Age 3 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit 106.84%
(FY 2023)
- Ebitda 92.10%
(FY 2023)
- Net Worth 4117.62%
(FY 2023)
- Total Assets 45531.91%
(FY 2023)
About Serum Institute Vaccines
The Corporate was formerly known as Pravotech Bio-Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1,200.00 Cr and a paid-up capital of Rs 113.26 Cr, as per Ministry of Corporate Affairs (MCA) records.
Saurabh Prabhudesai, Hrishikesh Ponkshe, and Prasad Vanarse serve as directors at the Company.
- CIN/LLPIN
U24100PN2021PTC200477
- Company No.
200477
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Apr 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Serum Institute Vaccines?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saurabh Prabhudesai  | Director | 03-Mar-2022 | Current |
| Hrishikesh Ponkshe | Director | 21-Apr-2021 | Current |
| Prasad Vanarse | Director | 21-Apr-2021 | Current |
Financial Performance and Corporate Structure Insights of Serum Institute Vaccines.
Serum Institute Vaccines Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 106.84% increase in profit. The company's net worth Soared by an impressive increase of 4117.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Serum Institute Vaccines?
In 2023, Serum Institute Vaccines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Poonawalla Estates Stud And Agri Farm Privae LimitedActive 18 years 8 monthsSaurabh Prabhudesai is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Serum Institute Vaccines?
Serum Institute Vaccines has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Serum Institute Vaccines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Serum Institute Vaccines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
